{Reference Type}: Journal Article
{Title}: Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials.
{Author}: Hamid A;Greene SJ;Mehta A;Butler J;Khan MS;
{Journal}: Curr Heart Fail Rep
{Volume}: 0
{Issue}: 0
{Year}: 2024 May 25
暂无{DOI}: 10.1007/s11897-024-00668-8
{Abstract}: <B>OBJECTIVE: </B>End stage kidney disease can be a slow process and it may be challenging to achieve required follow-up for sufficient events. Therefore, a surrogate kidney endpoint, such as estimated glomerular filtration rate (eGFR) slope maybe attractive to assess the kidney in cardiovascular trials, especially heart failure (HF).<BR><B>RESULTS: </B>eGFR slope can generate informative results in a shorter follow-up period, has decreased risk of type-2 error, and is less sensitive to eGFR shifts compared with other surrogate kidney endpoints (eGFR decline≥40% or doubling creatinine). However, eGFR slope has its limitations with acute effects, heterogeneity in slope calculation/reporting, and deviations from linearity. eGFR slope is a kidney endpoint which may be well-suited for HF trials. Cross-collaborated guideline recommendations are needed to optimize the use of eGFR slope as a kidney endpoint in patients with HF.